• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Long-term future of Priadel must be secured

12th December 2020 by PIP editor Leave a Comment

 

The Royal Pharmaceutical Society (RPS) and the College of Mental Health Pharmacists (CMHP) have written to the Competition and Markets Authority (CMA) as part of a consultation regarding the supply of Priadel, the lithium medication used by bipolar patients.

 

It comes following a campaign by the RPS, other royal colleges and patient groups which helped establish a new, low price for Priadel agreed by the Department of Health and Social Care (DHSC) and the drug manufacturer, Essential Pharma.

 

The letter asks for clarification on what will happen after the new price agreement contract expires for Priadel and calls for new regulatory changes to be put in place.

 

Sandra Gidley, President of the RPS said:

 

“We welcome the responsiveness of the CMA to the concerns that we’ve raised on the availability of Priadel. It is essential that we now get clarity on the drug’s long-term future, particularly regarding what will happen once this new price contract ends after the 5-year agreement. There has to be legislative changes made that will prevent other companies from exploiting patients and ensure that something like this will not happen again.”

 

Ciara Ni Dhubhlaing, President of the College of Mental Health Pharmacy, said:

 

“We cannot allow patient access to Priadel to be restricted in the future. This will mean thousands of vulnerable individuals are unnecessarily put at risk. It is vital that patients have confidence in the supply chain and ongoing access to their medicines; therefore more needs to be done to ensure the availability of this essential medicine continues.”

 

You can read the letter here.

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  GPhC publish new pharmacist education and training standards

Filed Under: News Tagged With: Lithium

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Pharmacists should not have to bend the rules

Pharmacists should follow Canada and be able to change prescriptions

Resitters: The forgotten pre-registration pharmacist cohort

Provisionally registered pharmacists should not have to sit the exam

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.